Sleep Medications for Elderly Patients
For elderly patients with insomnia, start with low-dose doxepin (3-6 mg) for sleep maintenance problems or ramelteon (8 mg) for sleep onset difficulties, as these have the best safety profiles in this age group. Avoid benzodiazepines and diphenhydramine due to increased fall risk, cognitive impairment, and other serious adverse effects in older adults 1.
Recommended First-Line Pharmacologic Options
For Sleep Maintenance Insomnia:
- Low-dose doxepin (3-6 mg): Specifically recommended for sleep maintenance with minimal anticholinergic effects at these doses 2, 3, 4
- Suvorexant (10 mg starting dose): Orexin receptor antagonist with no demonstrated abuse potential or significant motor/cognitive impairment 2
For Sleep Onset Insomnia:
- Ramelteon (8 mg): Melatonin receptor agonist with excellent safety profile, no abuse potential, and no withdrawal syndrome 2, 1, 4
- Zaleplon (5 mg in elderly): Short-acting option for sleep initiation 2, 3
For Both Sleep Onset and Maintenance:
- Eszopiclone (1-2 mg): Start at 1 mg for sleep onset, 2 mg for maintenance issues. Proven effective in elderly with acceptable tolerability 2, 5
- Zolpidem (5 mg in elderly): Lower doses required due to increased sensitivity 2, 3
Critical Dosing Considerations for Elderly
All medications must be started at the lowest available dose in elderly patients 1. Older adults have:
- Reduced drug clearance (pharmacokinetic changes)
- Increased sensitivity to peak drug effects (pharmacodynamic changes)
- Higher risk of adverse events including falls, confusion, and next-day impairment 1
Agents to AVOID in Elderly
Do not use the following medications 2, 1:
- Diphenhydramine and other antihistamines: Significant anticholinergic effects, increased fall risk, cognitive impairment, next-day sedation 2, 6
- Trazodone (50 mg): No systematic evidence for effectiveness; risks outweigh benefits 2, 1, 3
- Long-acting benzodiazepines: Excessive accumulation, falls, cognitive impairment 1
- Tiagabine: Not effective and should not be used 2, 3
- Standard melatonin (2 mg): Insufficient evidence for efficacy 2
Benzodiazepines: Use with Extreme Caution
While triazolam (0.25 mg) and temazepam (15 mg) have AASM recommendations for general adults 2, benzodiazepine receptor agonists (Z-drugs) have lower adverse effect frequency and severity compared to traditional benzodiazepines in elderly patients 1. The geriatric literature emphasizes that older adults are at greater risk for:
- Falls and fractures
- Cognitive impairment and confusion
- Dependence and withdrawal
- Next-day impairment
Special Consideration: Prolonged-Release Melatonin
For patients ≥55 years old, prolonged-release melatonin is authorized and replaces the physiological decline of endogenous melatonin with aging 6, 7. It:
- Induces sleep with soporific properties
- Improves sleep efficiency and morning alertness
- Has no withdrawal syndrome or abuse potential
- Carries no deleterious side effects when used at appropriate doses 6
Treatment Duration and Monitoring
- Z-drugs (zolpidem, zopiclone, zaleplon, eszopiclone) cannot be prescribed longer than 28 days 6
- Monitor for dose-dependent and time-dependent impairment 1
- Assess for drug interactions, particularly with CYP3A4 inhibitors/inducers when using eszopiclone 5
Clinical Algorithm
- Identify insomnia subtype: Sleep onset vs. maintenance vs. both
- Start lowest dose:
- Sleep onset only → Ramelteon 8 mg or zaleplon 5 mg
- Sleep maintenance only → Doxepin 3-6 mg or suvorexant 10 mg
- Both → Eszopiclone 1-2 mg or zolpidem 5 mg
- Avoid: Diphenhydramine, trazodone, long-acting benzodiazepines, tiagabine
- Consider prolonged-release melatonin if patient ≥55 years for physiologic replacement
- Limit Z-drug duration to ≤28 days
- Monitor closely for falls, confusion, next-day impairment
Common Pitfalls
- Using standard adult doses instead of reduced elderly doses
- Prescribing diphenhydramine or other OTC antihistamines (very common but contraindicated)
- Using trazodone off-label despite lack of evidence and significant risks 1, 3
- Continuing benzodiazepines long-term without reassessment
- Failing to recognize that nonbenzodiazepine receptor agonists still carry risks in elderly, though less than traditional benzodiazepines 1